NCT03938701: Fluorescence Imaging of IBD and RA Using Adalimumab-800CW
- State
- Under way
- Phase
- Phase 2
- People
- 36 planned
- Started
- 6 Aug 2024
- Primary completion
- Mar 2026
- Arms
- 1. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW, 2. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW, 3. Fluorescence imaging of inflammatory bowel disease and rheumatoid arthritis with adalimumab-800CW
- Results
- None posted
- 6 May 2019: Trial registered
- 6 Aug 2024: Trial started